NO985148L - FremgangsmÕte og formuleringer til Õ forhindre og/eller behandle alle infek - Google Patents

FremgangsmÕte og formuleringer til Õ forhindre og/eller behandle alle infek

Info

Publication number
NO985148L
NO985148L NO985148A NO985148A NO985148L NO 985148 L NO985148 L NO 985148L NO 985148 A NO985148 A NO 985148A NO 985148 A NO985148 A NO 985148A NO 985148 L NO985148 L NO 985148L
Authority
NO
Norway
Prior art keywords
infections
formulations
treat
procedures
prevent
Prior art date
Application number
NO985148A
Other languages
English (en)
Norwegian (no)
Other versions
NO985148D0 (no
Inventor
Michel G Bergeron
Andru Desormeaux
Michel Tremblay
Original Assignee
Michel G Bergeron
Andru Desormeaux
Michel Tremblay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michel G Bergeron, Andru Desormeaux, Michel Tremblay filed Critical Michel G Bergeron
Publication of NO985148D0 publication Critical patent/NO985148D0/no
Publication of NO985148L publication Critical patent/NO985148L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/912—Cancer cell repair
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO985148A 1996-05-09 1998-11-04 FremgangsmÕte og formuleringer til Õ forhindre og/eller behandle alle infek NO985148L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1710696P 1996-05-09 1996-05-09
PCT/CA1997/000319 WO1997042962A1 (fr) 1996-05-09 1997-05-09 Preparations servant a la prevention de maladies induites par des pathogenes tels que le vih ou le hsv

Publications (2)

Publication Number Publication Date
NO985148D0 NO985148D0 (no) 1998-11-04
NO985148L true NO985148L (no) 1999-01-08

Family

ID=21780760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985148A NO985148L (no) 1996-05-09 1998-11-04 FremgangsmÕte og formuleringer til Õ forhindre og/eller behandle alle infek

Country Status (17)

Country Link
US (1) US6068851A (fr)
EP (1) EP0930886B1 (fr)
JP (1) JP2000510836A (fr)
KR (1) KR20000010834A (fr)
CN (1) CN1177594C (fr)
AP (1) AP1406A (fr)
AT (1) ATE269711T1 (fr)
AU (1) AU723081B2 (fr)
BR (1) BR9709228A (fr)
CA (1) CA2258811C (fr)
DE (1) DE69729646T2 (fr)
HK (1) HK1019560A1 (fr)
IL (1) IL126804A0 (fr)
NO (1) NO985148L (fr)
NZ (1) NZ332578A (fr)
OA (1) OA11096A (fr)
WO (1) WO1997042962A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773994B1 (fr) * 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
US6482805B2 (en) * 1998-03-25 2002-11-19 Parker Hughes Institute AZT derivatives exhibiting spermicidal and anti-viral activity
US6191120B1 (en) * 1998-03-25 2001-02-20 Wayne Hughes Institute Spermicidally active 5-halo-6-alkoxy-5,6-dihydro-2′,3′-dideoxy-uridines and their pharamaceutical compositions
CN100374110C (zh) 1998-04-21 2008-03-12 瑞克尔科感染公司 含有泊洛沙姆和其它杀微生物剂的局部制剂,以及施用器
US6030957A (en) 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
US6541020B1 (en) * 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
ATE489937T1 (de) * 2000-03-07 2010-12-15 Rush Presbyterian St Luke Zusammensetzungen und deren verwendung zum abfangen und inaktivieren pathogener mikroben und spermatozoen
US6835717B2 (en) * 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
CA2411167A1 (fr) * 2000-06-23 2002-01-03 Merck & Co., Inc. Adjuvants de vaccins polynucleotidiques et formulations contenant des tensioactifs cationiques, procedes d'utilisation associes
US7465295B2 (en) 2000-10-20 2008-12-16 Bergeron Michel G Applicator for the delivery of topical formulations into mucosal cavities
AU2003205227A1 (en) * 2002-01-18 2003-09-02 Emory University Phthalocyanine and porphyrazine pharmaceutical compositions
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
AU2003275069A1 (en) * 2002-09-20 2004-04-08 La Jolla Biosciences Compositions and methods for preventing infection
US20130085146A1 (en) * 2003-01-14 2013-04-04 Rodney J.Y. Ho Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
US20050014719A1 (en) * 2003-06-24 2005-01-20 Khan Adil A. Method of controlling viral outbreak
US20050095283A1 (en) * 2003-09-16 2005-05-05 Aphios Corporation Compositions and methods for topically treating diseases
CA2561174A1 (fr) * 2004-03-26 2005-10-20 The University Of Utah Research Foundation Systeme polymere biosensible pour l'administration de microbicides
JP2007533755A (ja) * 2004-04-20 2007-11-22 ザ ユニヴァーシティ オヴ シカゴ 高分子量ｐｅｇ様化合物を含む治療薬送達システム
JP2006111585A (ja) * 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
US20070298094A1 (en) * 2004-11-18 2007-12-27 Terumo Kabushiki Kaisha Medicinal Composition, Preparation and Combined Preparation
US20060127459A1 (en) * 2004-12-15 2006-06-15 Lei Huang Urogenital infection inhibition
WO2006112632A1 (fr) * 2005-04-18 2006-10-26 Benjamin Won Park Comdoms uretraux et femidoms liquides
KR100775315B1 (ko) 2005-08-03 2007-11-08 벤자민 원 박 성병과 에이즈예방용 윤활젤 조성물
US20080078408A1 (en) * 2005-04-18 2008-04-03 Park Benjamin W Urethral condoms and liquid female condoms
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
US20070134747A1 (en) * 2005-12-14 2007-06-14 Kimberly-Clark Worldwide, Inc. Detection of secreted lipase proteins from Candida species
CN101662935A (zh) * 2007-05-04 2010-03-03 宝洁公司 抗微生物组合物、产品以及使用方法
WO2009073658A1 (fr) * 2007-12-03 2009-06-11 Trilogic Pharma Llc Implant barrière bioérodable à auto-solidification
WO2010045479A1 (fr) * 2008-10-15 2010-04-22 The Board Of Trustees Of The University Of Illinois Compositions micellaires et liposomales de phospholipide et leurs utilisations
DE102009034771B4 (de) * 2009-07-25 2011-09-01 Martin Schmitt Hautschutzmittel
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2011084610A1 (fr) * 2009-12-16 2011-07-14 Children Medical Center Corporation Liposomes utilisés en vue de la prévention de la transmission du vih
US10039709B2 (en) * 2010-06-04 2018-08-07 Trilogic Pharma Llc Bioadhesive compositions for epithelial drug delivery
JP6392209B2 (ja) * 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
CA2916002A1 (fr) 2013-06-25 2014-12-31 Mission Pharmacal Company Nouvelles formulations pour le traitement de troubles vaginaux
EP3250184A1 (fr) 2015-01-27 2017-12-06 The Johns Hopkins University Formulations d'hydrogel hypotoniques pour le transport amélioré d'agents actifs au niveau de surfaces muqueuses
EP3484485A1 (fr) 2016-07-12 2019-05-22 Centre National De La Recherche Scientifique Compositions utiles pour la cicatrisation des muqueuses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
IT1240354B (it) * 1990-03-30 1993-12-07 Poli Ind Chimica Spa Formulazioni liposomiali di farmaci antimicotici,antibatterici e/o antantiflogistici per applicazione locale e vaginale
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
IT1250748B (it) * 1991-08-02 1995-04-21 Poli Ind Chimica Spa Formulazioni utili per il trattamento della secchezza vaginale
IT1255460B (it) * 1992-07-28 1995-11-02 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
CA2173964A1 (fr) * 1993-10-15 1995-04-20 Jess G. Thoene Prevention de l'infection par le vih

Also Published As

Publication number Publication date
IL126804A0 (en) 1999-08-17
KR20000010834A (ko) 2000-02-25
AU723081B2 (en) 2000-08-17
ATE269711T1 (de) 2004-07-15
WO1997042962A1 (fr) 1997-11-20
JP2000510836A (ja) 2000-08-22
OA11096A (en) 2003-03-13
NZ332578A (en) 2000-06-23
AP9801382A0 (en) 1998-12-31
DE69729646T2 (de) 2005-07-07
NO985148D0 (no) 1998-11-04
EP0930886B1 (fr) 2004-06-23
CN1218403A (zh) 1999-06-02
CA2258811C (fr) 2003-11-25
HK1019560A1 (en) 2000-02-18
CA2258811A1 (fr) 1997-11-20
BR9709228A (pt) 1999-08-10
AU2629997A (en) 1997-12-05
EP0930886A1 (fr) 1999-07-28
AP1406A (en) 2005-05-04
CN1177594C (zh) 2004-12-01
US6068851A (en) 2000-05-30
DE69729646D1 (de) 2004-07-29

Similar Documents

Publication Publication Date Title
NO985148L (no) FremgangsmÕte og formuleringer til Õ forhindre og/eller behandle alle infek
NO992641D0 (no) Blandinger og fremgangsmÕter for behandling eller forhindring av betennelsessykdommer
DE69713202D1 (de) Einführungsvorrichtungen sowie Anordnungen
NO983266D0 (no) Distribuert Behandling
ATE246485T1 (de) Hautreinigungsmittel
DK0835637T3 (da) Behandlingstilbehør til endeskop
DK0834278T3 (da) Behandlingstilbehør til endoskop
IT1283817B1 (it) Attacco per tavola da neve
DK1035865T3 (da) HIV-1-Tat eller derivater deraf til profylaktisk og terapeutisk vaccination
NO20002849D0 (no) Sammensetninger og metoder for Õ indusere genekspersjon
DE59506122D1 (de) Haut-distraktor
NO993467D0 (no) Granuler som innbefatter klavulanat og en eller flere eksipienter
DK0901483T3 (da) Benzofuraner og benzopyraner som kronobiologiske midler
IS4805A (is) Aðferð til meðhöndlunar og lyfjasamsetning
DK1114821T3 (da) Benzopyraner og disses anvendelse som terapeutiske midler
NO991459L (no) Anvendelse av 1-hydroksy-2-pyridoner til behandling av hudinfeksjoner
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
DK0947079T3 (da) System og fremgangsmåder til internettelefoni
NO983263L (no) Distribuert behandling
NO993030D0 (no) FremgangsmÕte og system for Õ skaffe forbindelser
DK0791591T3 (da) Benzothiophener, formuleringer indeholdende samme og fremgangsmåder til deres fremstilling
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
DK0910369T3 (da) Benzothiophener, formuleringer indeholdende samme og fremgangsmåder
NO983672D0 (no) Prevensjonssystem med antibakteriell og/eller antivirus effekt
GB9726343D0 (en) The use of excipients to accelerate freeze-drying

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application